Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®

Trial Profile

Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aleglitazar (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms AleNEPHRO
  • Sponsors Roche

Most Recent Events

  • 25 Jun 2013 Results reporting lipid, glycaemic and insulin parameters presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
  • 11 Mar 2013 Results with focus on secondary endpoints presented at the 62nd Annual Scientific Session of the American College of Cardiology.
  • 05 Sep 2012 Primary endpoint 'Glomerular-filtration-rate' has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top